The European Union’s Medical Device Regulation (EU MDR)…
…which came into force in May 2017, has introduced significant changes to the regulatory landscape for medical devices in the EU. These changes have had a profound impact on medical device manufacturers, including those based in the United States, which is the largest global medical device market. The transition to the new regulatory framework has presented several challenges, particularly in terms of clinical evaluation, innovation, and the capacity of Notified Bodies (NBs).
Clinical Evaluation Challenges
The transition to EU MDR has increased the requirements for clinical evaluation, especially for high-risk devices. Manufacturers have faced challenges in identifying a clinical evaluation pathway, generating sufficient clinical evidence, and resolving clinical queries from Notified Bodies in a timely manner.
This has led to a reliance on external expertise and training to meet the enhanced requirements. Despite the U.S. being a major market for medical devices, many manufacturers have opted to launch new devices in the EU ahead of the U.S. due to previously lower clinical data requirements, faster approval times, and lower costs. However, the stricter MDR requirements have forced a reevaluation of this strategy, particularly for high-risk devices.
Impact on Innovation
The EU MDR has also had an impact on innovation within the medical device industry. The regulation has led to increased time to market for medical devices in the EU, partly due to the more comprehensive and detailed requirements compared to the previous Medical Device Directive (MDD).
This has resulted in some technologies leaving the EU market, as companies decide it is not worth investing in post-market surveillance for products with small volumes and profits. Consequently, European patients and clinicians may have fewer choices, and smaller companies may face a decline.
Notified Bodies and Implementation Challenges
A significant challenge in the implementation of EU MDR and IVDR has been the shortage of Notified Bodies (NBs) designated to facilitate transitions in a timely manner. This shortage, along with the absence of Implementing Acts to ensure compliance with emerging product requirements, has raised concerns among U.S. manufacturers about their continued access to the EU’s medical device market.
Looking Ahead
Despite these challenges, the EU MDR aims to enhance patient safety and increase trust in the medical device sector by introducing a strengthened notified body system, more transparency, stricter clinical evidence requirements, and a unique device identification system for supply chain traceability. However, the non-harmonized interpretation and application of MDR rules across the EU, limited capacity among Notified Bodies, and uncertainties regarding international recognition of MDR certifications continue to pose challenges for the industry.
In summary, the lack of resources and expertise in the U.S. regarding EU MDR experience stems from the significant changes and increased requirements introduced by the regulation. These challenges include the need for more detailed clinical evaluations, the impact on innovation and time to market, and the capacity and designation of Notified Bodies. As the industry continues to adapt to these changes, collaboration, external expertise, and training will be key to navigating the new regulatory landscape.
Stirling Q&R specializes in recruiting top talent with EU MDR experience to help medical device companies navigate the complexities of compliance. Their expertise can address the shortage of qualified professionals and streamline the transition to the new regulatory framework, ensuring timely market access and continued innovation
Schedule a Call
